Parkinson and a genetic reprogramming as treatment

0

A survey was conducted for technicians at the Karolinska Institute, and was tested in laboratories. This transform brain cells into producers of dopamine.

Parkinson’s disease affects the motor and brain capacities of patients, as well as scientists at the Karolinska Institute in Sweden, test a method of genetic reprogramming in laboratories, with the aim of transformed brain cells into dopamine-producing neurons which is the Neurotransmitter responsible for the function not brain and not body, including movement control, learning, mood, emotions, cognitive functions and memory.

With this experience, the models presented have improvements in terms of mobility and tremors. But Parkinson’s may lead to a slowing of movements and involuntary tremors due to the lack of dopamine, David Dexter, one of the scientists involved in the study, told Nature Biotechnology that this study “offers a new form of new cells that have been lost with the Parkinson’s disease”, and a replacement of cells is said by the researcher as “a possible way to reverse the symptoms of the disease”, and “one day, to lead to cure”.

This process is carried out by scientists, is manipulated as ordinary brain cells, which normally produce astrocytes, and then transform into cells to dopamine-producing neurons. After testing several genes that help create neurotransmitters this is possible. And the end result was obtained by combining four genes with other molecules that were injected into rats with Parkinson’s. These took about 2 to 5 weeks to begin to show improvement.

“What this study has is different”, explains Ernest Independent Arenas, who runs an experiment, “which uses a schedule to transform as astrocyte cells into a neuron that is functional in people.” For the past 6 years, it is being studied and is the first prototype of the genus, yet scientists still do not claim to be this new method and bring other complications to patients.

The Independent, Christopher Morris, professor of neurotoxicology at the University of Newcastle, study important questions about this study, namely, question the ability of new cells to produce their own dopamine and, for how long, these abilities to remain stable in mice of test.

At the moment, it is not known as causes that lead to the appearance of this disease, but a suspicion is that it is a result of a combination of genetic and environmental factors. This affects, above all, people from 50 years of age, only 1 in 20 presentations before 40 years.

Comment